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In this study, we evaluated the anti-reovirus activity of kuraridin isolated from the roots of Sophora
ﬂavescens. In particular, we focused on whether this property is attributable to direct inhibition of
reovirus attachment and/or inhibition of viral replication with the aid of time-of-addition (pre-treat-
ment, simultaneous treatment, and post-treatment) experiments. No signiﬁcant antiviral activity of
kuraridin was detected in the pre-treatment assay. In the simultaneous assay, the 50% effective inhibitory
concentrations (EC50) of kuraridin were 15.3e176.9 mM against human type 1e3 reoviruses (HRV1e3)
and Korean porcine reovirus (PRV). Kuraridin completely blocked binding of viral sigma 1 protein to sialic
acids at concentrations lower than 82.5 mM in the hemagglutination inhibition assay. Moreover, kuraridin
inhibited HRV1e3 and PRV viral replicationwith EC50 values of 14.0e62.0 mM. Quantitative real-time PCR
analysis disclosed strong suppression of reovirus RNA synthesis at the late stage (18 h) of virus repli-
cation by kuraridin. The viral yields of kuraridin-treated cells were signiﬁcantly reduced at 24 h post-
infection, compared with DMSO-treated cells. Our results collectively suggest that kuraridin inhibits
virus adsorption and replication by inhibiting hemagglutination, viral RNA and protein synthesis and
virus shedding, supporting its utility as a viable candidate antiviral drug against reoviruses.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Mammalian reovirus (MRV) is the prototype member of the
Reoviridae family of non-enveloped double-stranded RNA (dsRNA)
viruses, with a genome composed of ten segments. Reoviruses,
originally referred to as “respiratory enteric orphans”, were ﬁrst
isolated from humans in the United States and Mexico in the 1950s
(1). MRVs are represented by four prototype strains: type 1 Lang: þ82 63 570 5239.
: þ82 63 570 5239.
jpark@kribb.re.kr (S.-J. Park).
rmacological Society.
should be considered as ﬁrst
g by Elsevier B.V. on behalf of Japa
d/4.0/).(T1L), type 2 Jones (T2J), type 3 Dearing (T3D) and type 4 Ndelle
(T4N), with the majority of strains assigned to serogroups T1L, T2J
or T3D (2). Reoviruses have been isolated from the respiratory and
enteric tracts of children with mild respiratory or gastrointestinal
symptoms (1). However, limited studies have focused on human
reovirus-associated neurological disease to date (3). Pneumonia
and other respiratory diseases in both naturally and experimentally
infected primates (4), and isolation of reoviruses from childrenwith
meningitis and encephalitis are widely documented (5, 6).
MRVs infect awide range of hosts, including livestock (pig, cattle
and chickens), contributing to severe economic losses worldwide.
The use of antiviral agents is not commonplace because of their
toxicity and high production costs. Hence, effective and inexpen-
sive alternatives to antiviral drugs remain an urgent unmet medical
need (7). Many traditional medicinal plants display strong antiviralnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Fig. 1. The structure of kuraridin.
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animals and humans has been demonstrated (8, 9).
The life cycle of viruses is divided into several stages, including
cell surface attachment, penetration, uncoating, replication (pro-
tein synthesis) and release, all of which provide targets for antiviral
agents (9). Currently, more than 40 antiviral drugs are licensed for
the treatment of human immunodeﬁciency virus (HIV), hepatitis B
virus (HBV) and herpesviruses. However, the number of licensed
antiviral drugs for treatment of highly pathogenic RNA virus in-
fections remains limited (10). These viral diseases are considered
difﬁcult to treat with selective antiviral chemotherapy, highlighting
the need for further reﬁnement of antiviral drug design and
development. Medicinal plants have a variety of chemical constit-
uents, including alkaloids, tannins, saponins, ﬂavonoids, terpe-
noids, lignans and coumarins, known to inhibit the replication
cycles of various DNA and RNA virus types. Compounds derived
from natural sources are therefore of signiﬁcant interest as possible
sources of viral infection control (7e9).
Dried roots of Sophora ﬂavescens Ait. (S. ﬂavescens) have been
historically used in traditional Chinese herbal medicine, owing
their anti-inﬂammatory, antiarrhythmic, antipyretic, antiasthmatic,
and antiulcerative effects, and for the treatment of diarrhea,
gastrointestinal hemorrhage, and eczema (11). Additionally, a
formulation containing S. ﬂavescens is reported to inhibit angio-
genesis in a collagen-induced arthritis rat model (12). In previous
studies, quinolizidine alkaloids, ﬂavonoids, and triterpenoids were
isolated from the roots of S. ﬂavescens (13). Recently, quinolizidine
alkaloids and ﬂavonoids have been shown to exhibit a wideFig. 2. Antiviral assay strategies at different stages of virus infection. (A) Pre-treatment as
infection, (B) Simultaneous treatment assay: virus incubated with the MeOH extract, EtOAc
addition of the MeOH extract, EtOAc fraction or kuraridin at 1 h post-viral infection.spectrum of pharmacological activities, including anticancer, anti-
inﬂammatory, antitumor, cardioprotective, neuroprotective, anti-
bacterial, and anti-inﬂuenza properties (11,13e21). However, the
potential anti-reovirus activities of extracts and compounds iso-
lated from S. ﬂavescens have not been examined to date. In the
current investigation, we evaluated the abilities of the MeOH
extract, EtOAc fraction and kuraridin isolated from S. ﬂavescens to
inhibit human type 1e3 reoviruses (HRV1e3) and Korean porcine
reovirus (PRV). Antiviral assays were employed to determine
whether the S. ﬂavescens compounds alter reovirus activity by
inhibiting virus attachment and/or replication.
2. Materials and methods
2.1. Analytical equipment
The 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra were
obtained on JEOL ECS400 spectrometer, with CD3OD as a solvent.
The ESI-MS was determined using an Agilent 6430 LC/MS/MS and
1100 LC/MS spectrometer. Reversed-phase CCwas carried out using
RP-C18 silica gel (Cosmosil 140C18-PREP, 140 mm, Nacalai tesque,
INC.). Silica gel CC was conducted using Kieselgel 60 (70e230 and
230e400mesh, Merck). TLCwas conducted using Kieselgel 60 F254
plates (Merck).
2.2. Extract and isolation
The S. ﬂavescens were purchased at an herbal market in Jeon-
geup, Korea. A voucher specimen (PB-012e012) has been deposited
in the Korea Plant Extract Bank, Korea Research Institute of
Bioscience and Biotechnology. Dried roots of S. ﬂavescens (5 kg)
were extracted with MeOH (10 L) for 7 days at room temperature.
The MeOH extract was evaporated in vacuo, yielding a residue
(193 g). The residue was suspended in distilled water (1 L) and
extractedwith n-hexane, CHCl3, EtOAc and BuOH. In this process, n-
hexane (3.9 g), CHCl3 (22 g), EtOAc (33.5 g) and BuOH (38.9 g) layers
were obtained respectively. The EtOAc layer was submitted to open
column chromatography on silica gel (230e400 mesh, 300 g,say: addition of the MeOH extract, EtOAc fraction or kuraridin at 12 h prior to virus
fraction or kuraridin isolated from S. ﬂavescens at 4 C for 1 h, (C) Post-treatment assay:
H.-J. Kwon et al. / Journal of Pharmacological Sciences 128 (2015) 159e169 161Merck) using gradient solvent system CHCl3-EtOAc (100:1, 80:1,
50:1, 30:1, 10:1, 1:1, 1:10, 1:100; v/v, each 1L) as eluent to yield 21
fractions (F1eF21) by TLC proﬁle. F15 (2 g) was subjected to column
chromatography on ODS (70 g, Cosmosil 140C18-PREP, 140 mm,
Nacalai tesque, INC.) eluted with MeOHeH2O (50:50, 60:40, 70:30,
80:20, 90:10, 100:0; v/v, each 200 mL) to yielded 12 fractions
(F15e1~12) based on the TLC proﬁle. F15e9 (120 mg) was chro-
matographed on reverse-phase (10 g) column using a MeOHeH2O
solvent gradient (70:30, 80:20, 90:10, 100:0; v/v, each 50 mL) to
yield compound 1 (53mg). Compound 1was obtained as orange oil,
it exhibited a molecular ion peak at m/z 438 [MþH]þ in the ESI-MS
and molecular formula was determined as C26H30O6. The presence
of lavandulyl group was inferred from three methyl protons [d 1.55
(3H, s, H-600), 1.62 (3H, s, H-700), 1.70 (3H, s, H-1000)], three oleﬁnic
protons [d 5.03 (1H, m, H-400), 4.58 (1H, br s, H-900a), 4.53 (1H, br s,
H-900b)], two methylene protons [d 2.53 (1H, m, H-200), 2.06 (2H, m,
H-300)] and a multiple at d 2.61 (2H, m, H-100). The 13C NMR spec-
trum revealed the presence of 26 carbons as one carbonyl group,
three methylene carbons, four methyl carbons, eight methines and
ten quaternary carbons. Thus, the structure of compound 1 was
determined by spectroscopic analysis (MS and NMR) and comparedFig. 3. Cytotoxicity of the MeOH extract, EtOAc fraction, and kuraridin isolated from S. ﬂavesc
extract, EtOAc fraction (2.3e300 mg/mL) or kuraridin (2.3e300 mM) for 72 h. Cell viability wa
expressed as mean ± ANOVA combined standard error of three independent replicates. **Pwith the data published in the literature (22). The compound
identiﬁed was kuraridin (Fig. 1).
Kuraridin: Orange oil. C26H30O6. ESI-MS m/z: 439.5 [MþH]þ. 1H
NMR (400MHz, CD3OD): d 7.95 (1H, d, J¼ 15.6 Hz, H-2), 7.88 (1H, d,
J¼ 15.6 Hz, H-3), 7.39 (1H, d, J¼ 8.9 Hz, H-60), 6.34 (1H, d, J¼ 2.4 Hz,
H-30), 6.32 (1H, dd, J¼8.9, 2.4Hz,H-50), 5.99 (1H, s, H-6), 5.03 (1H,m,
H-400), 4.58 (1H, br s, H-900a), 4.53 (1H, br s, H-900b), 3.87 (3H, s, OCH3),
2.61 (2H,m, H-100), 2.53 (1H,m, H-200), 2.06 (2H,m, H-300),1.70 (3H, s,
H-1000), 1.62 (3H, s, H-700), 1.55 (3H, s, H-600). 13C NMR (100 MHz,
CD3OD): d 194.7 (C-4), 165.2 (C-5), 163.9 (C-7), 162.3 (C-9), 162.1 (C-
40), 160.2 (C-20), 149.7 (C-800), 139.7 (C-2), 131.7 (C-500), 131.5 (C-60),
125.3 (C-400), 125.0 (C-3), 116.2 (C-10), 111.1 (C-900), 108.8 (C-8), 108.7
(C-50), 106.4 (C-10), 103.5 (C-30), 91.4 (C-6), 56.0 (OCH3), 48.7 (C-200),
32.3 (C-300), 28.1 (C-100), 25.9 (C-600), 19.0 (C-1000), 17.8 (C-700).
2.3. Cells and viruses
Fetal rhesusmonkey kidney (TF-104) cells were grown in Eagle's
minimum essential medium (EMEM) supplemented with 5% fetal
bovine serum (FBS) and 100 U/mL penicillin, and 100 mg/mL
streptomycin and 100 U/mL amphotericin B. Cells were maintainedens on TF-104 cells. TF-104 cells were treated with various concentrations of the MeOH
s measured with the MTT assay, with DMSO-treated cells as the control group. Data are
< 0.01, *P < 0.05, compared to control DMSO-treated cells.
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H.-J. Kwon et al. / Journal of Pharmacological Sciences 128 (2015) 159e169162at 37 Cwith 5% CO2. Antibiotic, trypsin-EDTA, FBS, and EMEMwere
supplied by Gibco BRL (Grand Island, NY, USA). The reovirus Type 1
(Lang, ATCC VR-230), Type 2 (Jones, ATCC VR-231), Type 3 (Dearing,
ATCC VR-824) purchased from American Type Culture Collection
(ATCC) and PRV (KRP113 strain) isolated from fecal samples of
Korean diarrheic piglets were used in this study. Reoviruses were
preactivated with 10 mg/mL trypsin (GIBCO Invitrogen Corporation,
CA, USA) for 30 min at 37 C before being inoculated onto conﬂuent
TF-104 cells and infected cells were maintained in the presence of
1 mg/mL trypsin (GIBCO Invitrogen Corporation, CA, USA).
2.4. Cytotoxicity assay
TF-104 cells were grown in 96 well plates at 1  105 cells/well
for 48 h. The media in plates were replaced with media containing
serial diluted the MeOH extract, EtOAc fraction (2.3e350 mg/mL) or
kuraridin (2.3e350 mM) and incubated for 24 h or 72 h. The solution
was replaced with only media and 5 mL MTT (3e(4,5edimethyl
thiazole2eyl)e2,5ediphenyltetrazolium bromide, SIGMA) solu-
tion was added to each well and incubated at 37 C for 4 h. After
removal of supernatant, 100 mL 0.04 M HCl-isopropanol was added
for solubilization of formazan crystals. Absorbance was measured
at 540 nm with subtraction of the background measurement at
655 nm using a microplate reader. Cell viability was calculated as a
percentage of the total number of 0.5% DMSO-treated control cells.
The CC50 was calculated as described (23).
2.5. Antiviral assay
The antiviral assays have been previously described (24), and
the visualization of these assays was performed by neutral red
method as brieﬂy described.
Pre-treatment assay (Fig. 2A): TF-104 cells were grown in 96
well plates at 1  105 cells/well for 48 h. Before virus inoculation,
non-cytotoxic concentration (CC50) of the MeOH extract and
EtOAc fraction or kuraridin isolated from S. ﬂavescenswere added to
the cells and incubated for 12 h. Then extracts and compound were
removed and the TF-104 cells were washed 2 times with PBS.
Reoviruses at a multiplicity of infection (MOI) of 0.01 were inocu-
lated onto the TF-104 cells for 1 h with occasional rocking. The
media was removed and replaced by EMEM containing 1 mg/mL
trypsin. The cultures were incubated for 72 h at 37 C under 5% CO2
atmosphere until the cells in the infected, untreated control well
showed complete viral cytopathic effect (CPE) as observed by light
microscopy. Each concentration of extracts and compounds was
assayed in triplicate.
After 72 h incubation in all antiviral assays, 0.034% neutral red
was added to each well and incubated for 2 h at 37 C in the dark.
The neutral red solution was removed and the cells were washed
with PBS (pH 7.4). Destaining solution (containing 1% glacial acetic
acid, 49% H2O, and 50% ethanol) was added to each well. The plates
were incubated in the dark for 15 min at room temperature.
Absorbancewas read at 540 nm using amicroplate reader. The EC50
that is deﬁned as the concentration offering 50% inhibition of viral
yield in cells was calculated as described (23).
Simultaneous treatment assay (Fig. 2B): Various concentra-
tions of MeOH extract and EtOAc fraction or kuraridin were mixed
with virus at 0.01 MOI and incubated at 4 C for 1 h. The mixture
were inoculated onto near conﬂuent TF-104 cell monolayers
(1  105 cells/well) for 1 h with occasional rocking. The solution
was removed and the media was replaced. The cultures were
incubated for 72 h at 37 C under 5% CO2 atmosphere until the cells
in the infected, untreated control well showed complete viral CPE
as observed by light microscopy. Each concentration of extracts or
compound was assayed in triplicate.
Fig. 4. In vitro antiviral activity of the MeOH extract, EtOAc fraction, and kuraridin in simultaneous treatment assay and post treatment assay. (AeC) Simultaneous treatment assay: Reoviruses (HRV1e3 and PRV) infected the TF-104
cells were treated with serial concentrations of the MeOH extract (2.3e150 mg/mL) (A), EtOAc fraction (2.3e150 mg/mL) (B) or kuraridin (2.3e150 mM) (C) at the same time. After 1 h, reoviruses and the extracts and compound were
removed and the medium replaced. Cultures were incubated for 72 h at 37 C under 5% CO2. (DeF) Post treatment assay: Reoviruses infected TF-104 cells were treated with serial concentration of the MeOH extract (2.3e150 mg/mL) (D),
EtOAc fraction (2.3e150 mg/mL) (E) or kuraridin (2.3e150 mM) (F) for 72 h. The in vitro antiviral effect was evaluated using the neutral red assay. All assays were performed three times in triplicate. Non-infected and DMSO-treated group
was used as the negative control, and reovirus-infected and DMSO-treated group was used as the positive control.
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H.-J. Kwon et al. / Journal of Pharmacological Sciences 128 (2015) 159e169164Post treatment assay (Fig. 2C): Reoviruses at 0.01 MOI were
inoculated onto near conﬂuent TF-104 cell monolayers (1  105
cells/well) for 1 h with occasional rocking. The media was removed
and replaced by EMEM with MeOH extract and EtOAc fraction or
kuraridin at different concentration. The cultures were incubated
for 72 h at 37 C under 5% CO2 atmosphere until the cells in the
infected, untreated control well showed complete viral CPE as
observed by light microscopy. Each concentration of extracts and
compound was assayed for virus inhibition in triplicate.
2.6. Hemagglutination inhibition (HI) assay
The hemagglutination inhibition assay was performed to eval-
uate the effects of theMeOH extract and EtOAc fraction or kuraridin
on viral adsorption to target cells. The reoviruses solution (4 HAU/
25 mL) was mixed with an equal volume of the extracts or com-
pound (25 mL) in a two-fold serial dilution in PBS (pH 7.4) for 1 h at
4 C. The prepared solution 50 mL was mixed with an equal volume
of 1% human red blood cells (hRBC, type O) in HRV1 or 1% bovine
red blood cell (bRBC) in HRV2-3 and PRV suspension and incubated
for 1 h at room temperature (25, 26).
2.7. Reverse transcription and quantitative real-time PCR
TF-104 cells were grown to about 90% conﬂuence, infected with
HRV1e3 and PRV strain at 0.01MOI, and cultured in the presence of
kuraridin (30 mМ) for 6 h or 18 h. For dose-dependant inhibition,
TF-104 cells infected with PRV strain at 0.01 MOI were maintained
with kuraridin at different concentration (5e50 mМ) for 24 h. After
incubation, medium was removed. The cells were scraped off,
washed twice with PBS, and collected by centrifugation (500 g for
3 min). In order to determine the mRNA expression level of Large 1
(L1) gene of reoviruses, total RNAwas isolated using Qiagen RNeasy
mini kit (QIAGEN) according to manufacturer's instruction. The
primer sequences used for quantitative real-time PCR of viral RNA
were 50- GTG GCA GCG GTG GAT ACG -3’ (sense) and Reverse:
Reverse: 50- GCC CTC TGA TGA CAA GAT GGA -3' (antisense) (27).
The total RNA was reverse transcribed into cDNA using the High
Capacity RNA-to-cDNA master mix (Applied Biosystems) according
to the manufacturer's instruction. Reverse transcription was per-
formed at 42 C for 1 h. The enzyme was inactivated at 95 C for
5 min. The cDNA was stored at 20 C or directly used in quanti-
tative real-time PCR. Real-time PCR was conducted using 2 mL of
cDNA and Power SYBR Green PCR 2X master mix (Applied Bio-
systems). Cycling conditions for real-time PCR were as follows:Fig. 5. Inhibitory activities of the MeOH extract, EtOAc fraction, and kuraridin on viral he
glutinating units (HAU) of HRV1e3 and PRV were mixed with an equal volume of MeOH ex
incubated for 1 h at 4 C. Hemagglutination activity was examined following incubation wit
minimum concentrations of the extracts and kuraridin that completely inhibited viral hem95 C for 1 min, followed by 40 cycles of 95 C for 15 s and 60 C for
15 s. Real-time PCR was conducted using the Step One Plus Real-
time PCR system, and the data were analyzed with StepOne soft-
ware v2.1 (Applied Biosystems).
2.8. Confocal ﬂuorescence imaging
TF-104 cells were grown on 8-well chamber slides (LAB-TEK,
NUNC, USA), and the monolayers were infected with PRV at 1 MOI
for 1 h. The TF-104 cells were removed the virus solution and
replaced by EMEM with kuraridin (30 mM) under test. The cells
were cultured for 24 h at 37 C in a 5% CO2 atmosphere, washed
three times with PBS (pH 7.4), and ﬁxed in 4% paraformaldehyde
solution for 15 min at room temperature. After three times washed
with PBS (pH 7.4), cells were incubated at 37 C for 1 h with sigma 1
(s1)-speciﬁc monoclonal antibody against reovirus (Abcam, MA,
USA) diluted 1:50 in PBS (pH 7.4). After washing with PBS (pH 7.4),
cells were incubated at 37 C for 1 h with goat anti-mouse ﬂuo-
rescein isothiocyanate (FITC)-conjugated immunoglobulin G (IgG)
antibody (Santa Cruz, CA, USA) diluted 1:100 in PBS (pH 7.4). Cells
were washed with PBS (pH 7.4), stained with 500 nM 40,6-
diamidino-2-phenylindole (DAPI) solution for 10 min at room
temperature, and washed three times with PBS (pH 8.0). Slides
were mounted using SlowFade Gold antifade reagent (Invitrogen,
CA, USA). Confocal ﬂuorescence imaging was performed using a
Carl Zeiss LSM 510 META confocal microscope (Carl Zeiss Inc., Jena,
Germany).
2.9. Virus yield reduction assay
The TF-104 cells were infected with HRV1e3 and PRV strain at
0.01 MOI in 6-well plates. After 1 h of virus adsorption at 37 C, the
cells were washed three times with PBS and cultured in a medium
containing with MeOH extract and EtOAc fraction (20e150 mg/mL)
or kuraridin (6.25e50 mМ) at different concentration. The un-
treated cell and virus controls (0.5% DMSO) were included. The
supernatants were harvested after 24 h. The virus yields were
determined using plaque assay for 7 days. All determinations were
performed thrice in triplicate.
2.10. Statistical analysis
All experiments were repeated at least three times. The differ-
ences between groups were assessed using one-way or two-way
ANOVA, followed by Tuckey post-hoc analysis. Data weremagglutination with human RBC (hRBC, type O) or bovine RBC (bRBC). Four hemag-
tract, EtOAc fraction (A), kuraridin (B) or PBS (negative control) diluted two-fold, and
h 1% hRBC for HRV1 or 1% bRBC for HRV2e3 and PRV for 1 h at room temperature. The
agglutination were determined.
H.-J. Kwon et al. / Journal of Pharmacological Sciences 128 (2015) 159e169 165presented asmean± ANOVA combined standard errors of themean
(S.E.M). A values of P < 0.05 were considered to be signiﬁcant as
compared to the untreated control.3. Results
3.1. Cytotoxicity of S. ﬂavescens extracts and kuraridin to TF-104
cells
The cell viability of TF-104 cultures treatedwith the two extracts
and kuraridinwas evaluated using the MTT assay (Fig. 3). CC50 (50%
cytotoxic concentration) values for the MeOH extract and EtOAc
fraction were 253.3 and 278.4 mg/mL, respectively, while that for
kuraridin was considerably lower at 302.2 mM (Table 1).Fig. 6. Quantitative real-time PCR of reovirus viral RNA levels normalized to GAPDH. (A) TF-
removed 1 h post-infection. TF-104 cells were treated with DMSO (0.5%) or kuraridin (30 mM
levels measured. (B) TF-104 cells were infected with PRV at a MOI of 0.01. At 1 h post-infec
kuraridin (5, 10, 25, 50 mM). Total RNA was extracted 24 h post-infection, and the number of
standard error of three independent replicates. **P < 0.01, *P < 0.05, compared to control DAccordingly, all experiments evaluating antiviral effects were per-
formed at concentrations of minimal toxicity below 150 mg/mL for
the MeOH extract and EtOAc fraction or 150 mM for kuraridin.3.2. Inhibitory activity of S. ﬂavescens on reovirus adsorption
A pre-treatment assay was performed to examine the inhibitory
effect of the two extracts and kuraridin on reovirus attachment into
host cells (Fig. 2A). The simultaneous treatment assay was addi-
tionally conducted to determine whether the extracts and kurar-
idin directly inhibit reovirus particles (Fig. 2B). In the pre-treatment
assay, the MeOH extract, EtOAc fraction and kuraridin showed no
inhibitory effects against HRV1e3 and PRV (data not shown).
Notably, however, in the simultaneous treatment assay, two104 cells were infected with HRV1e3 and PRV at a MOI of 0.01. The viral inoculum was
). Total RNA was extracted at 6 h and 18 h post-infection, and the intracellular viral RNA
tion, the inoculum was removed. Next, TF-104 cells were treated with DMSO (0.5%) or
RNA copies of viral L1 gene measured. Data are expressed as mean ± ANOVA combined
MSO-treated cells.
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EtOAc fraction exhibited a decreasing order of antiviral activity
against HRV3, PRV, HRV1, and HRV2, while kuraridin exhibited
antiviral activity in a decreasing order against PRV, HRV3, HRV1,
and HRV2 (Table 1). Interestingly, our data indicate that both the
extracts and kuraridin exert stronger inhibitory effects on HRV3
and PRV than HRV1 or HRV2, with the greatest inhibitory effect
of kuraridin against PRV isolated from Korean porcine diarrheic
feces.
3.3. Hemagglutination inhibition (HI) activity
The simultaneous treatment assay established that either virus
adsorption or cell entry is inhibited by the two extracts and kur-
aridin. Accordingly, we evaluated whether the extracts and kurar-
idin inhibit reovirus-induced hemagglutination binding of HRV1 to
hRBC or HRV2e3 and PRV to bRBC. The MeOH extract and EtOAc
fraction completely inhibited HRV1 attachment to hRBCs as well as
HRV2e3 and PRV attachment to bRBCs at concentrations less than
92.5 mg/mL (Fig. 5), with a decreasing order of HI activity as follows:
PRV, HRV3, HRV2, and HRV1 for the MeOH extract, and PRV, HRV3,
HRV1, and HRV2 for the EtOAc fraction. Kuraridin exhibited a
similar decreasing order of HI activity against PRV, HRV3, HRV1, and
HRV2. Overall, the MeOH extract, EtOAc fraction, and kuraridin
showed stronger HI activity against HRV3 and PRV than HRV1 or
HRV2, consistent with the ﬁndings of the simultaneous assay. Our
results clearly indicate that strong interactions of the two extracts
and kuraridin with hemagglutinin on the outer-layer protein
(sigma 1) of reovirus result in inhibition of viral attachment.Fig. 7. Confocal ﬂuorescence imaging of kuraridin against reovirus. TF-104 cells were mock
kuraridin (30 mM) (C). After 24 h, cells were ﬁxed in 4% paraformaldehyde. After blocking
nuclear counterstain (blue). Bar ¼ 10 mm.3.4. Antiviral activity of S. ﬂavescens against reovirus replication
The post-treatment assay was performed to evaluate the inhib-
itory effects of the MeOH extract, EtOAc fraction, and kuraridin on
reovirus replication (Fig. 2C). The MeOH extract and EtOAc fraction
inhibited viral replication in preliminary experiments (Fig. 4B), with
a decreasing order of activity against HRV3, PRV, HRV2 and HRV1
(Table 1). Kuraridin exerted decreasing antiviral activity in the
following order: PRV, HRV3, HRV2, and HRV1 (Table 1). Similar to
the results of the simultaneous treatment assay, all three isolate
fractions showed stronger inhibitory effects on HRV3 and PRV than
HRV1 or HRV2. Viral RNA levels synthesized at the early and late
stages of virus infectionwere compared between kuraridin-treated
(30 mM) and untreated infected cells. RNA extractionwas performed
at 6 and 18 h post-infectionwith HRV1e3 and PRV, and the levels of
intracellular viral RNA measured via real-time PCR. Quantitative
real-time PCR data disclosed reduced reovirus RNA levels in
kuraridin-treated cells, compared with non-treated cells (0.5%
DMSO)HRV1e3 and PRV (Fig. 6A). Viral RNA inhibition in kuraridin-
treated cells was the greatest at late-stage (18 h) infection, indi-
cating that kuraridin (30 mM) inhibits viral RNA synthesis most
strongly at the late stage (18 h) than the early stage (6 h) of infection.
Furthermore, we observed dose-dependent inhibition of viral RNA
in PRV-infected TF-104 cells treated with 5e50 mM kuraridin for
24 h post-infection (Fig. 6B). The immunoﬂuorescence assay con-
ducted to investigate viral protein (sigma 1) inhibition by kuraridin
(30 mM) in PRV-infected TF-104 cells demonstrated green ﬂuores-
cence for virus-infected (Fig. 7B) but not mock-infected cells
(Fig. 7A). Treatment of cellswith kuraridin led to amarked reductioninfected (A) or infected with PRV at a MOI of 1 in the presence of DMSO (0.5%) (B) or
, cells were incubated with anti-sigma 1 (s1) antibody (green). DAPI was used as the
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determine the effects of the two extracts and kuraridin on reovirus
production, we performed the virus yield reduction assay. Viral
yields were estimated using a plaque assay. Notably, the MeOH
extract, EtOAc fraction, and kuraridin suppressed production of
HRV1e3 and PRV in a dose-dependentmanner indicating inhibition
of reovirus shedding or release (Fig. 8).
4. Discussion
Various steps of the viral replication cycle are targets of antiviral
agents, including adsorption, cell penetration, uncoating, tran-
scription, translation, assembly and viral release from infected cells
(4). We hypothesized that the antiviral effects of S. ﬂavescens can be
divided into two steps: 1) blockage of virus adsorption to cells and/
or 2) inhibition of viral replication after cell entry. Time-of-addition
experiments were performed to determine the stage at which
inhibitory activities are exerted. MeOH extract, EtOAc fraction, and
kuraridin of S. ﬂavescenswere added toTF-104 cells at three distinct
time-points, speciﬁcally, prior to infection (pre-treatment), at the
same time as virus infection (simultaneous) or post-infection (post-
treatment) (Fig. 2).
Reovirus entry into cells is a multistep process involving several
interactions between its outer layer protein (sigma 1 protein) and cellFig. 8. Reduction of reovirus production by the MeOH extract, EtOAc fraction, and kurarid
DMSO (0.5%), MeOH extract (20e150 mg/mL) (A), EtOAc fraction (20e150 mg/mL) (B) or kurar
determined with the plaque assay. Data are expressed as mean ± ANOVA combined standard
used as control.surface receptors, including sialic acid (SA) and junctional adhesion
molecule-A (JAM-A) (28). The sigma1protein speciﬁes tissue tropism
and is responsible for hemagglutination (HA) activity and binding of
SA (29, 30). The HA activity of reoviruses strongly implies a role of SA
in cell binding and infectivity of reoviruses, similar to inﬂuenza A
virus, rotavirus, various coronaviruses and Sendai virus (31). In the
current study, the HI assay was employed to assess the inhibitory
effects of the extracts and kuraridin on viral adsorption to host cells.
The MeOH extract and EtOAc fraction completely inhibited HRV1
adsorption to hRBCs aswell as HRV2e3 and PRV adsorption to bRBCs
at concentrations below 92.5 mg/mL. Kuraridin induced complete
inhibition of hemagglutination activity of HRV1 with hRBCs and
HRV2e3 and PRV with bRBCs at concentrations below 82.5 mM
(Fig. 5). I21nterestingly, the HI activity of kuraridin was stronger for
HRV3 and PRV than HRV1 and HRV2. These differences are linked to
sigma 1 protein sequences and possibly attributable to serotype-
speciﬁc interactions of viral proteins with different cell surface re-
ceptors. Five residues (Asn198, Arg202, Leu203, Pro204, and Gly205)
in sigma 1 protein are reported to play a role in reovirus and SA in-
teractions (32). Additionally, SA binding by sigma 1 protein of type 3
reovirus is mediated by an eight-stranded cross b-sheet of only the
T(iii) domain (residues 175e234) and hemagglutination by type 1
reovirusmediated by the T(iii) and T(iv) domains (residues 248e314)
(33). Thus, the diversity of sigma 1 protein according to type 1e3in. TF-104 cells were infected with HRV1e3 and PRV at MOI of 0.01, and treated with
idin (6.25e50 mM) (C). After 24 h, supernatant fractions were harvested and virus titers
error of three independent assays. *P < 0.05 compared to DMSO-treated cells that were
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nin on the protein. HI assay results were in agreement with those of
the simultaneous treatment assay (Table 1), indicating that the ex-
tracts and kuraridin potentially exert anti-reoviral activity via
blockage of viral attachment to SA at the host cell surface. Inhibition
of virus attachment, in turn, prevents virus entry, replication and
occurrence of infection.
The extracts and kuraridin signiﬁcantly inhibited reovirus repli-
cation after infection in a dose-dependent manner in the post-
treatment assay (Fig. 4B). Although the mechanisms by which kur-
aridin inhibits reovirus replication are currently unclear, the com-
pound is known to affect viral factors, such as RNA and protein. Our
experiments showed that viral RNA levels are signiﬁcantly lowered
by kuraridin. Interestingly, reoviral RNA synthesis was signiﬁcantly
inhibited by kuraridin at the late stage (18 h) of the viral replication
cycle for HRV3 and PRV (Fig. 6A). The reovirus replication cycle
comprises two distinct transcription phases (primary and second-
ary), which occur at early and late stages, respectively. For primary
transcription, viral RNA rapidly replicates at 6e8 h post-infection
within progeny viral particles. Secondary transcription is mediated
by particles assembled from the newly synthesized RNA and protein
molecules, and mature virions are produced at >12 h post-infection
(4). Our ﬁndings indicate that kuraridin inhibits viral protein syn-
thesis (sigma 1) to produce the same changes in viral RNA levels and
reduces virus shedding (Figs. 7 and 8). Based on these results, we
suggest that the kuraridin suppresses reovirus replication via inhi-
bition of viral RNA, protein synthesis and virus release.
Ribavirin is reported to exert anti-reovirus activity, inhibiting
viral multiplication (34). A number of natural products have been
extensively investigated for their antiviral and virucidal activities
(35e39). Gallate derivatives that display antiviral effects are used as
antioxidant food additives, including E310 (propyl gallate), E311
(octyl gallate), and E312 (lauryl gallate) (39). Mycophenolic acid
has additionally been identiﬁed as an anti-reoviral agent, acting as
a reversible inhibitor of eukaryotic IMP dehydrogenase (IMPDH)
(40). Another study demonstrated that chestnut and quebracho
wood extracts containing tannin show antiviral activity against
avian reovirus and metapneumovirus (41). The dipeptide,
benzyloxycarbonyl-Phe-Ala-ﬂuoromethyl ketone (Z-FA-FMK), is a
novel potent inhibitor of reovirus pathogenesis and oncolysis
in vivo (42). These drugs act by inhibiting reovirus replication and
adsorption, but their potential side-effects are yet to be clinically
evaluated. These natural products may be ideal candidates, since
they are less toxic, more effective, have fewer side-effects, and are
less expensive than commercially available anti-reovirus agents.
The results from the current study collectively indicate that com-
pounds isolated from S. ﬂavescens may be superior to anti-reovirus
agents, and further highlight the medical importance of identifying
effective natural antiviral agents.
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